AU2001294891A1 - Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the "classical" mitogen activated protein (map) kinase pathway - Google Patents

Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the "classical" mitogen activated protein (map) kinase pathway

Info

Publication number
AU2001294891A1
AU2001294891A1 AU2001294891A AU9489101A AU2001294891A1 AU 2001294891 A1 AU2001294891 A1 AU 2001294891A1 AU 2001294891 A AU2001294891 A AU 2001294891A AU 9489101 A AU9489101 A AU 9489101A AU 2001294891 A1 AU2001294891 A1 AU 2001294891A1
Authority
AU
Australia
Prior art keywords
classical
inhibition
map
combined
activated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294891A
Inventor
Yum Dai
Paul Dent
Steven Grant
Robert Mckinstry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of AU2001294891A1 publication Critical patent/AU2001294891A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
AU2001294891A 2000-09-28 2001-09-28 Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the "classical" mitogen activated protein (map) kinase pathway Abandoned AU2001294891A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23593800P 2000-09-28 2000-09-28
US60/235,938 2000-09-28
PCT/US2001/030508 WO2002026236A1 (en) 2000-09-28 2001-09-28 Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the 'classical' mitogen activated protein (map) kinase pathway

Publications (1)

Publication Number Publication Date
AU2001294891A1 true AU2001294891A1 (en) 2002-04-08

Family

ID=22887464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294891A Abandoned AU2001294891A1 (en) 2000-09-28 2001-09-28 Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the "classical" mitogen activated protein (map) kinase pathway

Country Status (3)

Country Link
US (1) US20040191168A1 (en)
AU (1) AU2001294891A1 (en)
WO (1) WO2002026236A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007531A2 (en) * 2002-07-17 2004-01-22 Arqule, Inc. Activated checkpoint therapy and methods of use thereof
WO2004041185A2 (en) * 2002-10-31 2004-05-21 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
WO2009099601A2 (en) * 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
RU2016133412A (en) * 2009-08-24 2018-12-10 Фидженикс, Инк. TARGETED IMPACT ON PAX2 FOR TREATMENT OF BREAST CANCER
WO2016019472A1 (en) * 2014-08-08 2016-02-11 Quest Pharmatech Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2246734A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US6214821B1 (en) * 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
US6247107B1 (en) * 1998-04-06 2001-06-12 Advanced Micro Devices, Inc. Chipset configured to perform data-directed prefetching
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Also Published As

Publication number Publication date
WO2002026236A9 (en) 2003-02-20
WO2002026236A1 (en) 2002-04-04
US20040191168A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20010013D0 (en) Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation and use as well as pharmaceutical preparations containing the compounds
ZA200006312B (en) Antibodies to CD23, derivatives thereof, and their therapeutic uses.
DE69928085D1 (en) DOSAGE FORM WITH EXTENDED ACTIVE SUBSTANCE
DE69810612T2 (en) Pharmaceutical compositions with plasma proteins
EE04293B1 (en) Stable lyophilized dosage forms
NO20032187D0 (en) Heterocyclylalkylpiperidine derivatives, their preparation and preparations containing the compounds
ATE331529T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTIGEN
DE69942928D1 (en) THERAPEUTIC FORMULATION FOR THE ADMINISTRATION OF TOLTERODIN WITH CONTROLLED RELEASE
NO960482D0 (en) The outsole
DE59915033D1 (en) Pharmaceutical preparation
DE69813602D1 (en) VENLAFAX-CONTAINING MEDICINE WITH EXTENDED ACTIVE SUBSTANCE
AU2001290078A1 (en) Stem cell therapy
ATE257700T1 (en) PHARMACEUTICAL COMBINATIONS WITH TRAMADOL
AU2001294891A1 (en) Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the "classical" mitogen activated protein (map) kinase pathway
DK1187847T3 (en) Streptogramin derivatives, their preparation and preparations containing these derivatives
FI101860B1 (en) Arrangement with anesthetic evaporator
FI964205A0 (en) Arrangement with anesthetic evaporator
AU4462900A (en) Novel peptides and the use thereof to control pests
DE69708130T2 (en) A-OXO-BUTANIC ACID CONTAINING PHARMACEUTICAL COMPOSITION
AU5211299A (en) Human checkpoint kinase
AU2001286407A1 (en) Antiviral compounds derived from the hsv gd protein and methods
ATE412405T1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED CARRIER
MA27184A1 (en) ANTI-INGAP ANTIBODY ASSAY
NO20030658D0 (en) Modulation of multiple lineage kinase proteins
WO2002029104A3 (en) Tumor marker and methods of use